SAN DIEGO (AP) — SAN DIEGO (AP) — Capricor Therapeutics Inc. (CAPR) on Wednesday reported a loss of $12.6 million in its third quarter.
The San Diego-based company said it had a loss of 38 cents per share.
The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.
The biotechnology company posted revenue of $2.3 million in the period, which also missed Street forecasts. Three analysts surveyed by Zacks expected $4 million.
Capricor shares have more than tripled since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $17.07, rising sixfold in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CAPR at https://www.zacks.com/ap/CAPR
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。